Invivyd Inc. (IVVD)
NASDAQ: IVVDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IVVD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $122.01M
- EPS (TTM)
- -$0.38
- Dividend yield
- None
- 52-week range
- 0.4127 – 3.01
- Day range
- 0.4127 – 0.4669
- Volume / Avg
- 5.30M / 5.20M
- Beta
- —
- Shares outstanding
- 295.63M
52-week range
IVVD stock today
On Nov 20, IVVD ended the session at $0.4127, shedding $0.0332 (7.45%), versus the S&P 500's 3.70% decline. Shares are 86.3% below their 52-week high of $3.01, set on Dec 23, 2025 and 0.0% above the 52-week low of $0.4127, near the bottom of the past year's range. IVVD is down 83.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 83.5%.
Invivyd has posted a net loss over the last twelve months (EPS of -$0.38), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Invivyd
Company profileInvivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Marc William Elia
- Headquarters
- New Haven, CT
- Employees
- 122
- IPO year
- 2021
- Website
- invivyd.com
Financial highlights
Full financialsIn fiscal 2025, Invivyd generated $53.4 million in revenue, up 110.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Invivyd reported a net loss of $52.5 million, compared with a loss of $169.9 million a year earlier. Operating margin was -104.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $53.43M | $25.38M | $0 | — | — |
| Growth | +110.47% | — | — | — | — |
| Net income | $-52.49M | $-169.93M | $-198.64M | $-241.32M | $-226.79M |
| EPS (diluted) | $-0.30 | $-1.43 | $-1.81 | $-2.23 | $-5.32 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$10.00+2323.07%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.10 vs $-0.11
- Surprise
- +9.09%
IVVD news
All IVVD news- Invivyd, Inc. Reports Q3 2026 PEMGARDA Net Product Revenue of $15.4 millionNasdaq
- Invivyd Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026GlobeNewswire
- Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination SyndromeGlobeNewswire
- Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report DataNasdaqABBV, AZN, CBLL, CDXS
Invivyd peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HUMAHumacyte Inc. | 0.4454 | -17.90% | $123.73M | vs IVVD |
| CMPXCompass Therapeutics Inc. | 0.6882 | +1.43% | $123.94M | vs IVVD |
| ENGNenGene Therapeutics Inc. | 1.74 | -1.14% | $116.61M | vs IVVD |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs IVVD |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs IVVD |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs IVVD |
| TARAProtara Therapeutics Inc. | 2.28 | -5.00% | $140.38M | vs IVVD |
| STROSutro Biopharma Inc. | 8.60 | -1.38% | $142.77M | vs IVVD |
Indexes, lists and sector
Invivyd stock FAQ
What is Invivyd's stock price today?
IVVD last traded at $0.4127 as of Nov 20, 4:00 PM EST, down 7.45% on the day. Prices are delayed at least 15 minutes.
Who is Invivyd's CEO?
Mr. Marc William Elia is the chief executive officer of Invivyd Inc., which has about 122 employees.
What is the IVVD 52-week high?
The 52-week high for IVVD is $3.01 and the 52-week low is $0.4127. The stock is currently 86.3% below its high.